Drug
LY 2140023 clinical trials
Also written LY2140023 and pomaglumetad methionil.
Includes 4 studies of Pomaglumetad methionil.
- studies test it
- 19
- open now
- 0
- in phase 3
- 4
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2011 (6)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 3
Denovo Biopharma LLC (15) · New York State Psychiatric Institute (1) · Eli Lilly and Company (1) · University of California, Los Angeles (1) · NYU Langone Health (1)
Often tested with
Tested in the same studies.
Ammonium Chloride (1) · Sodium Bicarbonate (1) · MP-101 (1) · Methamphetamine (1)
Studies
Open first, then newest update. How each study uses LY 2140023 is read from its arms, and is right about nine times in ten.
Testing it · 19
- The Effects of Urinary pH Changes on an Investigational Compound in Healthy SubjectsCompletedPhase 1Denovo Biopharma LLCNCT01440478Written as Ammonium Chloride + LY2140023
- A Comparator Study of LY2140023 Versus Placebo in Schizophrenia PatientsCompletedPhase 2Denovo Biopharma LLCNCT01086748Written as LY2140023
- A Study for Participants With SchizophreniaCompletedPhase 2Denovo Biopharma LLCNCT00520923Written as LY2140023
- A Long-Term, Open-Label, Study on SchizophreniaTerminatedPhase 2/3Denovo Biopharma LLCNCT01129674Written as LY2140023
- A Long-Term Safety Study of Pomaglumetad Methionil in SchizophreniaTerminatedPhase 3Denovo Biopharma LLCNCT01487083Written as Pomaglumetad methionil
- A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With SchizophreniaCompletedPhase 1Denovo Biopharma LLCNCT01606436Written as LY2140023
- A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsCompletedPhase 2Denovo Biopharma LLCNCT00845026Written as LY2140023
- A Study of LY2140023 in Patients With SchizophreniaTerminatedPhase 3Denovo Biopharma LLCNCT01307800Written as LY2140023
- A Physical Dependence Study in SchizophreniaCompletedPhase 3Denovo Biopharma LLCNCT01452919Written as LY2140023
- A Study of Safety and Tolerability in Subjects With SchizophreniaCompletedPhase 1Denovo Biopharma LLCNCT01354353Written as LY2140023
- A Study of LY2140023 in Schizophrenia Patients With Prominent Negative SymptomsCompletedPhase 2Denovo Biopharma LLCNCT01052103Written as LY2140023
- Glutamate Reducing Interventions in SchizophreniaCompletedPhase 1New York State Psychiatric InstituteNCT03321617Written as Pomaglumetad methionil
- A Study of LY2140023 in Hepatically-Impaired ParticipantsCompletedPhase 1Denovo Biopharma LLCNCT01475136Written as LY2140023
- A Study in Schizophrenic PatientsTerminatedPhase 2Denovo Biopharma LLCNCT01125358Written as LY2140023
- A Study of LY2140023 in Healthy ParticipantsWithdrawnPhase 1Denovo Biopharma LLCNCT01659177Written as LY2140023
- Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and PlaceboCompletedPhase 2Denovo Biopharma LLCNCT00149292Written as LY2140023
- Study of Pomaglumetad and MethamphetamineTerminatedPhase 1University of California, Los AngelesNCT03106571Written as Pomaglumetad methionil
- A mGlu2/3 Agonist in the Treatment of PTSDTerminatedPhase 1NYU Langone HealthNCT02234687Written as Pomaglumetad Methionil 160mg
- A Study of LY2979165 and LY2140023 in Healthy VolunteersCompletedPhase 1Eli Lilly and CompanyNCT01524237Written as LY2140023
Given in every arm · 3 — LY 2140023 is usual care beside what is tested
- A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsTerminatedPhase 3Denovo Biopharma LLCNCT01328093Written as LY2140023
- A Study of LY2140023 in Healthy ParticipantsCompletedPhase 1Denovo Biopharma LLCNCT01609218Written as LY2140023
- A Study of LY2140023 in Healthy ParticipantsCompletedPhase 1Denovo Biopharma LLCNCT01637142Written as LY2140023